Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study

Surcel, 2015, Preferences in the management of high-risk prostate cancer among urologists in Europe: results of a web-based survey, BJU Int, 115, 571, 10.1111/bju.12796 van den Bergh, 2016, Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence after local curative treatment: a systematic review, Eur Urol, 69, 802, 10.1016/j.eururo.2015.11.023 Cornford, 2017, EAU-ESTRO-SIOG guidelines on prostate cancer. part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer, Eur Urol, 71, 630, 10.1016/j.eururo.2016.08.002 Parker, 2017, Identification of site-specific recurrence following primary radiation therapy for prostate cancer using C-11 choline positron emission tomography/computed tomography: a nomogram for predicting extrapelvic disease, Eur Urol, 71, 340, 10.1016/j.eururo.2016.08.055 Sobol, 2017, Contemporary mapping of post-prostatectomy prostate cancer relapse with 11C-choline positron emission tomography and multiparametric magnetic resonance imaging, J Urol, 197, 129, 10.1016/j.juro.2016.07.073 De Bruycker, 2017, Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy, BJU Int, 120, 815, 10.1111/bju.13938 Parker, 2017, Patterns of recurrence after postprostatectomy fossa radiation therapy identified by c-11 choline positron emission tomography/computed tomography, Int J Radiat Oncol Biol Phys, 97, 526, 10.1016/j.ijrobp.2016.11.014 Ost, 2015, Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature, Eur Urol, 67, 852, 10.1016/j.eururo.2014.09.004 Ploussard, 2015, Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature, J Urol, 194, 983, 10.1016/j.juro.2015.04.103 Ost, 2018, Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): a prospective, randomized, multicentre phase II trial, J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853 Rischke, 2015, Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only, Strahlenther Onkol, 191, 310, 10.1007/s00066-014-0763-5 Karnes, 2015, Salvage lymph node dissection for prostate cancer nodal recurrence detected by C-11-choline positron emission tomography/computerized tomography, J Urol, 193, 111, 10.1016/j.juro.2014.08.082 Ost, 2016, Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis, Eur Urol, 69, 9, 10.1016/j.eururo.2015.07.004 Ost, 2016, Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences, Clin Oncol (R Coll Radiol), 28, e115, 10.1016/j.clon.2016.04.040 Team RC. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.r-project.org/2016. Schweizer, 2013, Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy, Ann Oncol, 24, 2881, 10.1093/annonc/mdt335 Yossepowitch, 2007, The natural history of noncastrate metastatic prostate cancer after radical prostatectomy, Eur Urol, 51, 940, 10.1016/j.eururo.2006.10.045 Sridharan, 2016, Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial, Radiother Oncol, 121, 98, 10.1016/j.radonc.2016.07.021 Ost, 2014, Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer, Prostate, 74, 297, 10.1002/pros.22750 Duchesne, 2016, Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial, Lancet Oncol, 17, 727, 10.1016/S1470-2045(16)00107-8 Hong, 2015, Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer, Nat Commun, 6, 6605, 10.1038/ncomms7605 Gundem, 2015, The evolutionary history of lethal metastatic prostate cancer, Nature, 520, 353, 10.1038/nature14347 Freedland, 2005, Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy, JAMA, 294, 433, 10.1001/jama.294.4.433 Pound, 1999, Natural history of progression after PSA elevation following radical prostatectomy, JAMA, 281, 1591, 10.1001/jama.281.17.1591 Abdollah, 2014, Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer, J Clin Oncol, 32, 3939, 10.1200/JCO.2013.54.7893 Perera, 2016, Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis, Eur Urol, 70, 926, 10.1016/j.eururo.2016.06.021 Gillessen, 2018, Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017, Eur Urol, 73, 178, 10.1016/j.eururo.2017.06.002 Sineshaw, 2015, Declining use of radiotherapy for adverse features after radical prostatectomy: results from the National Cancer Data Base, Eur Urol, 68, 768, 10.1016/j.eururo.2015.04.003